Kenya BioVax Institute 🇰🇪

Building the skills and expertise needed to manufacture vaccines locally was central to discussions as Kenya @BioVaxInstitute, led by CEO Dr @wronoh, welcomed a delegation from the Physikalisch-Technische Bundesanstalt (PTB). The delegation comprised Dr Christina Foerg-Wimmer, Ms Jennifer Gache, Mr Oliver Wroblowski and Mr Dominik Wershofen. The engagement explored opportunities for collaboration in pharmaceutical technology, including preventive maintenance training, quality control and vaccine regulation. These areas offer opportunities to equip KBI’s teams with the capabilities to advance local research, development and manufacturing of vaccines and other biological products, supporting Kenya’s journey towards reliable access to locally manufactured vaccines. #KenyaBioVax #PTB #VaccineManufacturing #CapacityBuilding #LocalManufacturing #VaccineResearch #QualityAssurance #HealthPartnerships #VaccineSecurity

🎉👏 @BioVaxInstitute has improved its Performance Contract rating from “Good” to “Very Good” following the FY 2025/2026 evaluation! 🏆 This milestone reflects our commitment to accountability, continuous improvement and delivery of our mandate. We celebrate the collective efforts of our Board, Management and staff in advancing our strategic objectives and strengthening the foundations for local vaccine and other health product manufacturing. As we mark this achievement, we remain focused on translating institutional performance into greater health security and access to critical health products for Kenya and the region. 🇰🇪 #KenyaBioVax #PerformanceExcellence #LocalManufacturing #HealthSecurity @KeTreasury @NAssemblyKE @OfficePCS_KE @LabourSPKE @NGCSKE

📢 Join Kenya BioVax Institute’s Vaccine Science Webinar Series! How do we navigate the regulatory requirements that support vaccine quality, safety and efficacy? Join us for an insightful session on “Navigating Regulatory Requirements for Vaccines”, bringing together professionals, researchers, students and stakeholders interested in vaccine development and regulation. 🗓️ Wednesday, 28 October 2026 🕒 3:00–4:30 pm EAT 💻 Online 🎤 Speaker: Dr. Geoffrey Okelo 🎙️ Moderators: Dr. @Muteru03 | Dr. @WinterOkoth Deepen your understanding of vaccine regulatory requirements and join a discussion on advancing vaccines from development to public health impact. Save the date and join the conversation! #KenyaBioVax #VaccineScience #VaccineRegulation #Vaccines #PublicHealth Register here: events.teams.microsoft.com/e…

🇰🇪 Happy Mashujaa Day! Kenya BioVax Institute honours the heroes whose courage and service continue to build our nation. We celebrate the healthcare workers, scientists, and everyday champions who are building a healthier, more resilient Kenya. To all our heroes—tunawashukuru. #HappyMashujaaDay #MashujaaDay #KenyaBioVax #OurHeroes

🇯🇵🇰🇪 Strengthening partnerships to support local access to vaccines and health products, Dr. Serah Muteru held discussions with the Global Health Innovative Technology (@GlobalHealth) Fund on potential areas of collaboration. The engagement formed part of her visit to Japan, strengthening Kenya @BioVaxInstitute’s ties with Japanese partners and supporting its mandate to build local vaccine and health product manufacturing capacity in Kenya. #KenyaBioVax #LocalManufacturing #KenyaJapan

Access to safe, quality healthcare products starts with strengthening the capacity to produce them closer to the people who need them. This ambition shaped Kenya @BioVaxInstitute’s participation in @jica_directJapan Visit Program in Tokyo from 8–15 October 2026, where General Manager, Regulatory Affairs, Quality and Safety, Dr. @Muteru03 joined a Kenyan delegation alongside @ppbkenya and @NQCLKenya. Speaking at the Kenya-Japan Health Investment and Co-Creation Dialogue on 10 October, she shared KBI’s vision for local manufacturing in Kenya. The programme explored regulatory harmonization and Kenya-Japan collaboration, with visits to the National Institute of Infectious Diseases, Fujirebio and Mediceo offering opportunities to learn from Japan’s healthcare expertise. #KenyaBioVax #LocalManufacturing #KenyaJapan 🇯🇵 🇰🇪

Linking local and diaspora talent is essential to building the expertise needed for a strong vaccine manufacturing ecosystem. This formed the focus of a meeting between @BioVaxInstitute and Innovare Health Collective, bringing together Kenya BioVax CEO, Dr @wronoh, General Manager, Commercial Services, Dr @cecilia_wanjala, and General Manager, Production, Dr Meshack Odenyo, with Carol Banks, CEO and Founder of Innovare Health Collective. Discussions explored partnerships to connect professionals interested in biomanufacturing with opportunities across the vaccine value chain, including deploying diaspora experts, knowledge transfer, and capacity building. The meeting also considered using artificial intelligence to support talent matching, strengthen collaboration, and advance innovation in vaccine manufacturing. #KenyaBioVax #InnovareHealthCollective #VaccineManufacturing #Biomanufacturing #DiasporaTalent #KnowledgeTransfer #CapacityBuilding #ArtificialIntelligence #HealthInnovation #StrategicPartnerships

@BioVaxInstitute hosted @AfricaCDC & @CEPIvaccines to assess vaccine manufacturing readiness, technology transfer, capacity building, manufacturer matchmaking, collaboration, and partnerships. The team met with technical and administrative staff and toured the mRNA lab. @BioVaxInstitute hosted a joint assessment visit by @AfricaCDC and @CEPIvaccines to explore opportunities to strengthen its vaccine manufacturing capacity. The delegation comprised Habtamu Antenel, Senior Technical Officer for Technology Transfer at Africa CDC, and Visah Mukund Sonje, Senior Vaccines Manufacturing Lead at CEPI. They met with BioVax’s technical and administrative teams to discuss capacity-development priorities and opportunities to matchmake with vaccine manufacturers to support partnerships and technology transfer. The delegation also toured the mRNA laboratory to learn about BioVax’s research and technical capabilities. The visit provided an opportunity to discuss how collaboration with Africa CDC, CEPI, and manufacturing partners could support the Institute’s progress towards local vaccine production and contribute to Africa’s vaccine manufacturing ambitions. #VaccineManufacturing #BioVax @WHOKenya @MOH_Kenya @MOHMedServices @KEMRI_Kenya

Opportunities to strengthen Kenya’s pharmaceutical and biotechnology capacity for domestic and export markets were the focus of discussions between 🇰🇪@BioVaxInstitute CEO Dr. @wronoh and Prof. Soyoun Kim, CEO of PCL Inc., 🇰🇷South Korea. The meeting explored a potential partnership to establish a pilot-scale, end-to-end biomanufacturing facility compliant with Good Manufacturing Practice (GMP), providing a platform to develop production processes, build technical expertise, and support the transition from research to manufacturing. The discussions also considered how collaboration could advance technology transfer and strengthen local capacity to produce quality vaccines and biotherapeutics, contributing to Kenya’s health security and positioning the country to serve regional and international markets. @KEMRI_Kenya @Samsungbio_news #KenyaBioVax #PCLInc #KEMRI #Biomanufacturing #Biotechnology #LocalManufacturing #TechnologyTransfer #VaccineManufacturing #HealthSecurity #KenyaSouthKorea

Culture of Science Conference 2026 brought together scientists, policymakers, innovators, and industry leaders to advance conversations on strengthening Africa’s research, innovation, and knowledge ecosystems under the theme “Shaping Africa’s Future through Science.” Dr. Meshack Odenyo, General Manager, Production at Kenya BioVax Institute, represented the CEO of @BioVaxInstitute during the conference, contributing to discussions on “Scaling Local Manufacturing and Innovation.” The session explored pathways to strengthen Africa’s pharmaceutical and biologics manufacturing capacity through improved financing, procurement frameworks, quality infrastructure, technology transfer, and sustainable local production. Dr. Odenyo shared Kenya BioVax’s commitment to advancing vaccine manufacturing, building local capacity, and supporting Africa’s aspiration for greater vaccine self-reliance through innovation and strategic partnerships. #KenyaBioVax #CultureOfScience #VaccineManufacturing #Biomanufacturing #HealthInnovation #ScienceForAfrica #AfricanInnovation #PublicHealth #ResearchAndInnovation #LocalManufacturing

The second day of the #PharmaRegAfriSummit2026 featured a panel discussion on advancing clinical trial infrastructure and research frameworks in Africa. Moderated by Prof. Shital Mahindra Maru, the session brought together regulatory and industry experts, including Dr. Serah Muteru of Kenya BioVax Institute, to discuss strengthening systems that support vaccine and biologics development. Dr. Serah Muteru highlighted the importance of building local capacity for sustainable human vaccine manufacturing through investment in skilled workforce, regulatory systems, quality management, clinical research and technology transfer partnerships to strengthen Africa’s health security. #KenyaBioVax #VaccineManufacturing #ClinicalResearch #HealthSecurity #MadeInAfrica #AfricanHealthInnovation

BioVax's Vaccine Science Webinar Series - From Antigen Discovery to Next-Generation Vaccines You’ve been invited to: BioVax's Vaccine Science Webinar Series - From Antigen Discovery to Next-Generation Vaccines Speaker: Prof. @FaithOsier (@IVIHeadquarters ) Date: Tuesday, 29th September 2026, Time: 3:00 – 4:00 pm EAT. Moderator: Dr. @WinterOkoth , PhD This will be a valuable opportunity to gain insights into next-generation vaccines; kindly make time to attend. It is open to the public. Register using the link below: events.teams.microsoft.com/e… Meeting ID: 397 612 844 168 528 Passcode: Wi2rc7P5

The sixth PharmaReg #AfriSummit2026, held at @OSereni Hotel in Nairobi under the theme “Building the Bridge of Health,” served as a continental platform for more than 450 delegates to exchange expertise, strengthen regulatory cooperation and explore practical approaches for expanding African production of pharmaceuticals and medical devices while supporting equitable access to essential healthcare. Opening the five-day Summit, Chief Guest and Cabinet Secretary for @MOH_Kenya , Hon. @HonAdenDuale, highlighted Kenya’s efforts to reduce dependence on imported health products through the 2026–2030 Health Products and Technologies Local Manufacturing Strategy, which targets the local production of at least 50 per cent of essential health products. @BioVaxInstitute participated in the discussions, contributing to dialogue on regulatory harmonization, strategic partnerships and sustainable local production to strengthen Africa’s manufacturing ecosystem and expand access to safe, effective and quality-assured vaccines, specialized biologics and other essential health products. #PharmaRegAfriSummit2026 #KenyaBioVax #LocalManufacturing #VaccineManufacturing #RegulatoryHarmonisation #HealthSecurity #UniversalHealthCoverage #MadeInAfrica #BuildingTheBridgeOfHealth @MOHMedServices

Dr. Willy Tonui, Founder of the @AfricaGeneBioAfrica , and his team paid a courtesy call on the CEO of @BioVaxInstitute, Dr @wronoh. The discussions explored potential areas of collaboration in biosafety, including opportunities to strengthen institutional capacity, promote responsible biotechnology practices, and advance safe and sustainable health innovations. Kenya BioVax remains committed to building strategic partnerships that support Kenya’s biosafety priorities and contribute to the growth of the country’s biotechnology and biomanufacturing ecosystem. #KenyaBioVax #Biosafety #Biotechnology #Biocontrol #StrategicPartnerships #HealthInnovation #Biomanufacturing #ResearchAndInnovation #PublicHealth #AfricaGeneticBiocontrolConsortium

@BioVaxInstitute , in partnership with the @MOH_Kenya and @PATHtweets, convened the Market Landscape Stakeholder Consultation Workshop on Vaccine and Specialized Biologics Manufacturing. The workshop brought together stakeholders from regulatory, procurement, research, financing, and development-partner institutions to review and validate evidence on Kenya’s health needs, vaccine demand, budgets, pricing, procurement systems, manufacturing complexity, regulatory requirements, and the broader African market. The consultation marked a transition from planning to evidence-based validation and decision-making, with participants assessing potential vaccine and specialized biologics products against public-health relevance, manufacturing feasibility, technology access, quality requirements, supply-chain resilience, sustainable financing and market competitiveness. The engagement will support identifying defensible product priorities and the practical interventions needed to strengthen Kenya’s manufacturing infrastructure, skilled workforce, regulatory readiness, technology-transfer partnerships, and capacity to produce safe, effective, affordable, quality-assured vaccines and specialized biologics for Kenya and the region. #KenyaBioVax #VaccineManufacturing #Biomanufacturing #HealthSecurity @IVIHeadquarters @ppbkenya @VaccinesKenya @UNICEFKenya @MOHMedServices